Germany-based Immatics Biotechnologies GmbH has launched a subsidiary in the US with the support of the MD Anderson Cancer Center in order to develop adoptive cellular therapies for the treatment of a range of cancers. ---Subscribe to MedNous to access this article--- Company News Research & University News
